Donald Trump & Kenvue

Donald Trump: Donald Trump publicly supported Robert F. Kennedy Jr.'s unproven claims about Tylenol and autism, urging pregnant women and parents not to use the pain reliever, which drew criticism from medical experts.

Kenvue: Kenvue, the manufacturer of Tylenol, refuted the claims made by Robert F. Kennedy Jr. and Donald Trump, stating that studies have found no causal link between acetaminophen use during pregnancy and fetal developmental issues.

Kenvue: Kenvue, the maker of Tylenol, disputed any link between the drug and autism. Its shares fell 7.5% in trading, reducing its market value by about $2.6 billion due to Donald Trump's statements.

Kenvue: Kenvue, the manufacturer of Tylenol, strongly disagreed with the suggestion that acetaminophen causes autism, defending the drug's safety and warning of risks from untreated fever or pain.

Kenvue: Kenvue is being acquired by Kimberly-Clark for $48.7 billion, providing a significant premium to its shareholders. Kenvue's stock surged after the announcement, despite facing scrutiny over Tylenol and activist investor pressure.

Kenvue: Kenvue, a spin-off of Johnson & Johnson, is a primary defendant in the United States — Texas lawsuit, accused of deceptively marketing Tylenol and facing claims of liability transfer from Johnson & Johnson. Kenvue's shares fell following the news.

Kenvue: Kenvue, the manufacturer of Tylenol (paracetamol), faced a lawsuit regarding alleged links between its product and autism, which was dismissed. The new study supports the safety of its product.